WO2021091434A3 - Генно-инженерная конструкция для стимуляции ангиогенеза - Google Patents

Генно-инженерная конструкция для стимуляции ангиогенеза Download PDF

Info

Publication number
WO2021091434A3
WO2021091434A3 PCT/RU2021/050002 RU2021050002W WO2021091434A3 WO 2021091434 A3 WO2021091434 A3 WO 2021091434A3 RU 2021050002 W RU2021050002 W RU 2021050002W WO 2021091434 A3 WO2021091434 A3 WO 2021091434A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
genetic engineering
angiogenesis
blood supply
growth factor
Prior art date
Application number
PCT/RU2021/050002
Other languages
English (en)
French (fr)
Other versions
WO2021091434A8 (ru
WO2021091434A2 (ru
WO2021091434A9 (ru
Inventor
Екатерина Александровна СЛОБОДКИНА
Максим Николаевич КАРАГЯУР
Вадим Юрьевич Балабаньян
Елена Викторовна ПАРФЕНОВА
Павел Игоревич МАКАРЕВИЧ
Жанна Алексеевна АКОПЯН
Всеволод Арсеньевич ТКАЧУК
Мария Александровна БОЛДЫРЕВА
Original Assignee
Общество С Ограниченной Ответственностью "Генная И Клеточная Терапия"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Генная И Клеточная Терапия" filed Critical Общество С Ограниченной Ответственностью "Генная И Клеточная Терапия"
Publication of WO2021091434A2 publication Critical patent/WO2021091434A2/ru
Publication of WO2021091434A8 publication Critical patent/WO2021091434A8/ru
Publication of WO2021091434A9 publication Critical patent/WO2021091434A9/ru
Publication of WO2021091434A3 publication Critical patent/WO2021091434A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Изобретение относится к области биотехнологии, конкретно, к генно-инженерным конструкциям для стимуляции ангиогенеза, и может быть использовано в медицине для лечения заболеваний, обусловленных нарушением кровоснабжения тканей. Предложена плазмидная бицистронная конструкция, несущая ген hHGF фактора роста гепатоцитов человека и ген hVEGF165 фактора роста эндотелия сосудов, с двумя отдельными промото- рами для каждого из генов: промотора цитомегаловируса - pCMV для гена HGF и промо- тора гена β-актина цыпленка – pCAG для гена VEGF165. Бицистронная конструкция может быть использована в качестве лекарственного средства для обеспечения стимуляции ангиогенеза, роста и ремоделирования сосудов, а также восстановления кровоснабжения в ишемизированных тканях. Изобретение позволяет достигать оптимальных концентраций и соотношения ангиогенных факторов роста (АФР).
PCT/RU2021/050002 2019-11-06 2021-01-05 Генно-инженерная конструкция для стимуляции ангиогенеза WO2021091434A2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2019135603A RU2737487C1 (ru) 2019-11-06 2019-11-06 Генно-инженерная конструкция для стимуляции ангиогенеза
RU2019135603 2019-11-06

Publications (4)

Publication Number Publication Date
WO2021091434A2 WO2021091434A2 (ru) 2021-05-14
WO2021091434A8 WO2021091434A8 (ru) 2021-06-10
WO2021091434A9 WO2021091434A9 (ru) 2021-07-08
WO2021091434A3 true WO2021091434A3 (ru) 2021-09-23

Family

ID=73792491

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2021/050002 WO2021091434A2 (ru) 2019-11-06 2021-01-05 Генно-инженерная конструкция для стимуляции ангиогенеза

Country Status (2)

Country Link
RU (1) RU2737487C1 (ru)
WO (1) WO2021091434A2 (ru)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022176A1 (en) * 2000-09-15 2002-03-21 Genvec, Inc. Method of modulating neovascularization
CN102242148A (zh) * 2010-10-09 2011-11-16 苏州大学 重组载体以及转基因骨髓基质细胞修饰的丝素膜及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1204247C (zh) * 2001-06-15 2005-06-01 中国人民解放军军事医学科学院百环生物医学研究中心 一种重组腺病毒及其在心肌缺血治疗中的应用
RU2449799C2 (ru) * 2009-10-30 2012-05-10 Федеральное Государственное Учреждение "Российский кардиологический научно-производственный комплекс Федерального агентства по высокотехнологичной медицинской помощи" Средство для осуществления терапевтического ангиогенеза и способ его осуществления

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022176A1 (en) * 2000-09-15 2002-03-21 Genvec, Inc. Method of modulating neovascularization
CN102242148A (zh) * 2010-10-09 2011-11-16 苏州大学 重组载体以及转基因骨髓基质细胞修饰的丝素膜及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAKAREVICH PAVEL ET AL: "Combined Transfer of Human VEGF165 and HGF Genes Renders Potent Angiogenic Effect in Ischemic Skeletal Muscle", PLOS ONE, vol. 7, no. 6, 13 June 2012 (2012-06-13), pages e38776, XP055826391, DOI: 10.1371/journal.pone.0038776 *
SLOBODKINA E A: "Development of a plasmid construct encoding HGF and VEGF165 for gene therapy.", EUROPEAN SOCIETY OF GENE & CELL THERAPY GENE AND CELL THERAPY (SFTCG) LAUSANNE, P469, 1 December 2018 (2018-12-01), pages 1 - 169, XP055826478, Retrieved from the Internet <URL:https://www.liebertpub.com/doi/pdfplus/10.1089/hum.2018.29077.abstracts> [retrieved on 20210721] *
YOON C S ET AL: "Sonoporation of the Minicircle-VEGF165 for Wound Healing of Diabetic Mice", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 26, no. 4, 8 November 2008 (2008-11-08), pages 794 - 801, XP019686117, ISSN: 1573-904X *

Also Published As

Publication number Publication date
WO2021091434A8 (ru) 2021-06-10
WO2021091434A2 (ru) 2021-05-14
WO2021091434A9 (ru) 2021-07-08
RU2737487C1 (ru) 2020-12-01

Similar Documents

Publication Publication Date Title
Desmet et al. Nanomedicines and gene therapy for the delivery of growth factors to improve perfusion and oxygenation in wound healing
Markkanen et al. Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart–gene therapy
US7297475B2 (en) Medicament injection kit and medicament injection method
EP0883343A1 (en) Method for treating ischemic tissue
JP2009526571A (ja) 遺伝子発現の熱的制御または電磁気的制御のための方法および遺伝子発現の熱的制御または電磁気的制御のための装置
Mao et al. Potential suppression of the high glucose and insulin-induced retinal neovascularization by Sirtuin 3 in the human retinal endothelial cells
Bejjani et al. Electrically assisted ocular gene therapy
Won et al. Functional polymers of gene delivery for treatment of myocardial infarct
EA031883B1 (ru) Способ ингибирования и/или снижения образования рубцовой ткани
Bikfalvi Angiogenesis: health and disease
WO2021091434A3 (ru) Генно-инженерная конструкция для стимуляции ангиогенеза
US20090048191A1 (en) Therapeutic molecules for modulating stability of vegf
US20090275509A1 (en) Method for stimulating angiogenesis using dkk2 and composition comprising the same
US20090149381A1 (en) Methods of regulating angiogenesis through stabilization of PEDF
US7709450B2 (en) Stimulation of vascularization with VEGF-B-186
Lebas et al. Therapeutic benefits and adverse effects of combined proangiogenic gene therapy in mouse critical leg ischemia
Zacchigna et al. Gene therapy perspectives for nerve repair
Xu et al. Cardiac-specific expression of the hepatocyte growth factor (HGF) under the control of a TnIc promoter confers a heart protective effect after myocardial infarction (MI)
RU2449799C2 (ru) Средство для осуществления терапевтического ангиогенеза и способ его осуществления
Marx Angiogenesis research comes of age: The discovery of agents that stimulate angiogenesis—the growth of new blood vessels—has sparked interest in the research
Donati et al. Angiogenesis and the progress of vascular and tumor biology: a tribute to Judah Folkman
JP4554940B2 (ja) ヒト胎盤由来の間葉系細胞を含む医薬及び該細胞を用いたｖｅｇｆの製造方法
Picichè et al. Enhancement of noncoronary collateral circulation: the hypothesis of an alternative treatment for ischemic heart disease
RU2628706C2 (ru) Способ стимуляции ангиогенеза в ишеминизированных тканях и комбинированное лекарственное средство для осуществления способа
Kawasuji Therapeutic angiogenesis for ischemic heart disease

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 26/09/2022)

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21714281

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 21714281

Country of ref document: EP

Kind code of ref document: A2